Bio-Techne Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $33.06
- Today's High:
- $33.99
- Open Price:
- $33.25
- 52W Low:
- $67.4718
- 52W High:
- $90.3605
- Prev. Close:
- $33.52
- Volume:
- 105252
Company Statistics
- Market Cap.:
- $11.33 billion
- Book Value:
- 12.475
- Revenue TTM:
- $1.14 billion
- Operating Margin TTM:
- 24.73%
- Gross Profit TTM:
- $770.22 million
- Profit Margin:
- 25.1%
- Return on Assets TTM:
- 7.12%
- Return on Equity TTM:
- 15.57%
Company Profile
Bio-Techne Corp had its IPO on 1989-02-09 under the ticker symbol TECH.
The company operates in the Healthcare sector and Biotechnology industry. Bio-Techne Corp has a staff strength of 3,050 employees.
Stock update
Shares of Bio-Techne Corp opened at $33.25 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of $33.06 - $33.99, and closed at $33.59.
This is a +0.21% increase from the previous day's closing price.
A total volume of 105,252 shares were traded at the close of the day’s session.
In the last one week, shares of Bio-Techne Corp have increased by +1.45%.
Bio-Techne Corp's Key Ratios
Bio-Techne Corp has a market cap of $11.33 billion, indicating a price to book ratio of 7.7815 and a price to sales ratio of 11.8254.
In the last 12-months Bio-Techne Corp’s revenue was $1.14 billion with a gross profit of $770.22 million and an EBITDA of $344.05 million. The EBITDA ratio measures Bio-Techne Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bio-Techne Corp’s operating margin was 24.73% while its return on assets stood at 7.12% with a return of equity of 15.57%.
In Q2, Bio-Techne Corp’s quarterly earnings growth was a positive 20.7% while revenue growth was a positive 4.5%.
Bio-Techne Corp’s PE and PEG Ratio
- Forward PE
- 42.1941
- Trailing PE
- 40.6989
- PEG
- 1.1476
Its diluted EPS in the last 12-months stands at $1.76 per share while it has a forward price to earnings multiple of 42.1941 and a PEG multiple of 1.1476. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bio-Techne Corp’s profitability.
Bio-Techne Corp stock is trading at a EV to sales ratio of 12.3173 and a EV to EBITDA ratio of 30.4276. Its price to sales ratio in the trailing 12-months stood at 11.8254.
Bio-Techne Corp stock pays annual dividends of $0.32 per share, indicating a yield of 0.45% and a payout ratio of 28%.
Balance sheet and cash flow metrics
- Total Assets
- $2.64 billion
- Total Liabilities
- $128.51 million
- Operating Cash Flow
- $-4756000.00
- Capital Expenditure
- $10.83 million
- Dividend Payout Ratio
- 28%
Bio-Techne Corp ended 2024 with $2.64 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.64 billion while shareholder equity stood at $1.97 billion.
Bio-Techne Corp ended 2024 with $88.98 million in deferred long-term liabilities, $128.51 million in other current liabilities, 1576000.00 in common stock, $1.31 billion in retained earnings and $872.74 million in goodwill. Its cash balance stood at $180.57 million and cash and short-term investments were $204.31 million. The company’s total short-term debt was $11,199,000 while long-term debt stood at $350.00 million.
Bio-Techne Corp’s total current assets stands at $621.48 million while long-term investments were $0 and short-term investments were $23.74 million. Its net receivables were $218.47 million compared to accounts payable of $77.31 million and inventory worth $171.64 million.
In 2024, Bio-Techne Corp's operating cash flow was $-4756000.00 while its capital expenditure stood at $10.83 million.
Comparatively, Bio-Techne Corp paid $0.28 in dividends in 2024.
Other key metrics
- Current Trading Price
- $33.59
- 52-Week High
- $90.3605
- 52-Week Low
- $67.4718
- Analyst Target Price
- $100.99
Bio-Techne Corp stock is currently trading at $33.59 per share. It touched a 52-week high of $90.3605 and a 52-week low of $90.3605. Analysts tracking the stock have a 12-month average target price of $100.99.
Its 50-day moving average was $31.58 and 200-day moving average was $30.13 The short ratio stood at 3.54 indicating a short percent outstanding of 0%.
Around 105.4% of the company’s stock are held by insiders while 9553.4% are held by institutions.
Frequently Asked Questions About Bio-Techne Corp
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.